New Drug Target for Neurodegenerative Disease?
Written on Jul 30, 2010
Researchers in California may have discovered new drug targets to treat an incurable hereditary disease that leads to loss of motor coordination, dementia and death. The Buck Institute for Age Research announced that it had identified a family of enzymes involved in the processes that cause...
Researchers Develop Implantable Glucose Monitoring Device for Diabetics
Written on Jul 29, 2010
Researchers at the University of California San Diego and GlySens Inc. are developing an implantable wireless sensor to continuously monitor blood sugar in diabetes patients, Reuters reports. The device could bring scientists one step closer to developing an “artificial pancreas” to manage...
Encouraging Fragile X Data for Seaside Therapeutics
Written on Jul 27, 2010
Seaside Therapeutics reported encouraging results from the largest randomized study conducted to date in patients with Fragile X syndrome, the most common cause of mental impairment and the most common known cause of autism. In the Phase II study of STX209, pediatric patients with severe sociability...
AML Remission Maintenance, Apoptotic Inducing Therapeutics, Topical Analgesic
Written on Jul 27, 2010
The Company is a biopharmaceutical company that has established a diverse drug development platform to actualize therapeutics indicated for the treatment of cancer and neuropathic pain. The company’s lead cancer product is a depressor amine therapeutic that is used in conjunction with cytokine therapy to...
Monoclonal Antibody Therapeutics
Written on Jul 27, 2010
The company is a specialty biopharmaceutical company that utilizes an immunology-based drug development platform to actualize therapeutics indicated for cancer and autoimmune disease. The company’s methodology functions by first identifying disease specific markers, or antigens, on afflicted biological...
Prostate Cancer, Ultrasound Thermal Therapy
Written on Jul 27, 2010
The company is a medical devices company that has developed a novel therapeutic technology for the treatment of prostate cancer. The company’s apparatus uses non-invasive MRI imaging to identify prostate cell masses, and a trans-urethral ultrasound applicator that delivers precise thermal energy to tumor...
Nitric Oxide Synthase Inhibitor Therapeutics, Pain Management
Written on Jul 27, 2010
The company is a specialty biopharmaceutical company that develops therapeutics for the treatment of chronic pain. The company’s drug development platform focuses on the production of small molecule therapeutics that inhibit the bioactive protein Nitric Oxide Synthase (nNOS), which has been shown to...
